Advaxis, Inc. (NASDAQ:ADXS) Reports 3Q19 Loss Restricted

Share on Stocktwits

Advaxis, Inc. (NASDAQ:ADXS) a clinical stage biotechnology company, on Monday released third quarter financial results before market open.

The company communicated loss of $ 9.86 million or $ 1.00 per share, compared with loss of $ 14.02 million or $ 3.99 per share, a year ago period.

The revenue for the third quarter down 99.12 percent to $ 0.01 million from $ 1.13 million in the same quarter last year

Kenneth A. Berlin, President and Chief Executive Officer, said, We believe the data generated from our ADXS-NEO program has provided valuable immunological insight that will be applicable across our neoantigen programs.

Follow Us on StockTwits